{"url_path":"/sec/stro/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-224170-index.html","accession_number":"0001193125-26-224170","cik":"0001382101","ticker":"STRO","issuer_name":"SUTRO BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-224170-index.html","primary_entity_key":"0001382101","primary_entity_name":"SUTRO BIOPHARMA, INC."},"word_count":324,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nThe exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, below.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\nForm\n\n \n\nFile No.\n\n \n\nExhibit\n\nFiling\n\nDate\n\n \n\nExhibit\nNo.\n\n \n\nFiled/Furnished\n\nHerewith\n\n31.1\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](stro-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n31.2\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](stro-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n32.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](stro-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n32.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](stro-ex32_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.INS\n\n \n\nInline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n104\n\n \n\nThe cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL and contained in Exhibit 101.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n* This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n \n\n \n\n94\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nSUTRO BIOPHARMA, INC.\n\nDate: May 14, 2026\n\nBy:\n\n/s/ Jane Chung\n\nJane Chung\n\nChief Executive Officer\n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Gregory Chow\n\nGregory Chow\n\nChief Financial Officer\n\n \n\n95"}